Evofem Biosciences Stock Z Score
EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem |
Evofem Biosciences OTC Stock Z Score Analysis
Evofem Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Evofem Biosciences Z Score | -30.0 |
Most of Evofem Biosciences' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionAccording to the company's disclosures, Evofem Biosciences has a Z Score of -30.0. This is 544.44% lower than that of the Pharmaceuticals sector and notably lower than that of the Health Care industry. The z score for all United States stocks is notably higher than that of the company.
Evofem Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in z score category among its peers.
Evofem Fundamentals
Return On Equity | -3.87 | ||||
Return On Asset | -1.25 | ||||
Operating Margin | (5.41) % | ||||
Current Valuation | 112.69 M | ||||
Shares Outstanding | 121.22 M | ||||
Shares Owned By Insiders | 0.28 % | ||||
Shares Owned By Institutions | 0.57 % | ||||
Number Of Shares Shorted | 8.68 M | ||||
Price To Earning | (1.26) X | ||||
Price To Book | 8.37 X | ||||
Price To Sales | 0.42 X | ||||
Revenue | 8.24 M | ||||
Gross Profit | 4.19 M | ||||
EBITDA | (204.14 M) | ||||
Net Income | (205.19 M) | ||||
Cash And Equivalents | 19.89 M | ||||
Cash Per Share | 0.23 X | ||||
Total Debt | 125.74 M | ||||
Debt To Equity | 8.72 % | ||||
Current Ratio | 0.16 X | ||||
Book Value Per Share | (0.77) X | ||||
Cash Flow From Operations | (146.67 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (19.01) X | ||||
Target Price | 2.9 | ||||
Number Of Employees | 119 | ||||
Beta | -1.25 | ||||
Market Capitalization | 6.41 M | ||||
Total Asset | 42.51 M | ||||
Retained Earnings | (526.68 M) | ||||
Working Capital | 3.78 M | ||||
Current Asset | 16.39 M | ||||
Current Liabilities | 12.61 M | ||||
Z Score | -30.0 | ||||
Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |